Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

Chiu, Y.L. & Rana, T.M. siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034–1048 (2003).

Layzer, J.M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766–771 (2004).

Morrissey, D.V. et al. Activity of stabilized siRNAs in a mouse model of HBV replication. Hepatology 41, 1349–1356 (2005).

Ambegia, E. et al. Stabilized plasmid–lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim. Biophys. Acta 1669, 155–163 (2005).

Bally, M., Mayer, L., Hope, M. & Nayar, R. Pharmacodynamics of liposomal drug carriers: methodological considerations. in Liposome Technology, vol. III, 27–41, (CRC Press, London, 1993).

Fenske, D.B., MacLachlan, I. & Cullis, P. Long circulating vectors for the systemic delivery of genes. Curr. Opin. Mol. Ther. 3, 153–158 (2001).

Fenske, D.B., MacLachlan, I. & Cullis, P.R. Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol. 346, 36–71 (2002).

Judge, A. et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457–462 (2005).

Hornung, V. et al. Sequence-specific potent induction of IFN-a by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263–270 (2005).

Liu, F., Song, Y. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258–1266 (1999).

Yang, P.L., Althage, A., Chung, J. & Chisari, F.V. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 99, 13825–13830 (2002).

Samuel, C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778–809 (2001).

Kim, D.H. et al. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22, 321–325 (2004).

Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004).

Wincott, F. et al. Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res. 23, 2677–2684 (1995).

Wheeler, J.J. et al. Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 6, 271–281 (1999).

Jeffs, L. et al. A scalable, extrusion free method for efficient liposomal encapsulation of plasmid DNA. Pharm. Res. 22, 362–372 (2005).

Sandberg, J.A. et al. Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. Pharmacol. 40, 1462–1469 (2000).

Buckwold, V.E., Xu, Z., Chen, M., Yen, T.S. & Ou, J.H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 70, 5845–5851 (1996).